Valneva says it will not appeal MHRA decision
Valneva disagrees with conclusions by CHM and the MHRA and says it has decided not to appeal, citing immaterial financial and commercial impact.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.
News Feed
2 results loaded, newest first. End of these results. The latest changes are still being indexed. Try again shortly for updated results.
Valneva says UK revokes IXCHIQ vaccine authorization
Valneva said the UK MHRA revoked the marketing authorization for IXCHIQ after a further benefit-risk assessment by the CHM. The company said it expects no recall expense and only minimal impact on sales because it had not actively distributed the vaccine in the UK for months.